ArticleThe oncologist2021
Article in The oncologist, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 25 citations in OpenAlex.
- Application of theranostics in thyroid cancer management.The Journal of clinical endocrinology and metabolism · 2026Review
- Predictive value of 68[Ga]Ga-DOTA-TATE PET/CT volumetric parameters in assessing treatment response to long-acting somatostatin analogues in patients with well-differentiated neuroendocrine tumours.EJNMMI research · 2024Article
- Combining [European journal of nuclear medicine and molecular imaging · 2024Article
- Cardiac Neuroendocrine Tumor Metastases onJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives.Military Medical Research · 2024Review
- Expression of somatostatin receptors in hemangioblastomas associated with von Hippel-Lindau disease as a novel diagnostic, therapeutic, and follow-up opportunity: A case report and literature review.Archives of endocrinology and metabolism · 2024Review
- Reference myocardial uptake values on somatostatin receptor-targeted PET: not yet in preference to visual assessment.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Potential clinical utility ofJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Standardized Uptake Values on SPECT/CT: A Promising Alternative Tool for Treatment Evaluation and Prognosis of Metastatic Neuroendocrine Tumours.Diagnostics (Basel, Switzerland) · 2023Article
- Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists.Abdominal radiology (New York) · 2022Review
- Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs).Cancers · 2022Review
- Role of CombinedDiagnostics (Basel, Switzerland) · 2022Review
- Novel Tracers and Radionuclides in PET Imaging.Radiologic clinics of North America · 2021Review
- Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion.Cancer research and treatment · 2021Review
- Ga-68-Edotreotide PET/CT SSTR Total Tumor Volume as a Predictor of Outcome in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors.Cancer control : journal of the Moffitt Cancer CenterObservational
- Ga-68-Edotreotide Positron Emission Tomography/Computed Tomography Somatostatin Receptors Tumor Volume Predicts Outcome in Patients With Primary Gastroenteropancreatic Neuroendocrine Tumors.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSomatostatin analogs (SSAs) are the frontline antitumor therapy in advanced well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). A subset of patients demonstrate early disease progression on SSA therapy, yet the currently known predictors for treatment failure lack specificity to affect therapeutic decision. SSAs target tumor somatostatin receptors, the level of which can be quantitatively assessed with MATERIALS AND
methodsThe records of 108 consecutive patients with well-differentiated grade 1-2 GEP-NETs on SSA monotherapy who received
results
conclusionLow SUVmax on IMPLICATIONS FOR PRACTICE: Based on
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.